Online inquiry

IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3615MR)

This product GTTS-WQ3615MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets FGFR2 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000141.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2263
UniProt ID P21802
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3615MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5277MR IVTScrip™ mRNA-Anti-IL4-α, CD124(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CD124
GTTS-WQ12109MR IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MORAb-003
GTTS-WQ9955MR IVTScrip™ mRNA-Anti-hly, KBSA301(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA KBSA301
GTTS-WQ10336MR IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LY 3090106
GTTS-WQ1839MR IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AG1-25
GTTS-WQ7163MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-28Z CAR
GTTS-WQ11144MR IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MDX-1103
GTTS-WQ5234MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CB 2679d
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW